公开(公告)号：US20180232951A1

公开(公告)日：2018-08-16

申请号：US15576619

申请日：2016-05-23

Applicant: The University of North Carolina at Chapel Hill ,  Vanderbilt University

Inventor： Ron Alterovitz ,  Luis Guillermo Torres ,  Philip Joseph Swaney ,  Hunter Bryant Gilbert ,  Robert James Webster ,  Richard Joseph Hendrick

IPC: G06T19/00 ,  A61B1/01 ,  A61B34/30

CPC classification number: G06T19/003 ,  A61B1/01 ,  A61B1/2676 ,  A61B34/30 ,  A61B90/361 ,  A61B2034/301 ,  G06T19/00 ,  G06T2210/21 ,  G06T2210/41

Abstract: Systems for controlling concentric tube probes are disclosed. In some examples, the system includes a concentric tube position display interface and a control system. The concentric tube display interface includes a display for displaying visual feedback to a user indicating a position (and possibly orientation) of a tip of a concentric tube probe and a user input device for receiving user input from the user designating a goal position (and possibly orientation) for the tip of the concentric tube probe. The control system is configured for interactive-rate motion planning of the concentric tube probe by creating, in real-time or near real-time, a motion plan to move the tip of the concentric tube probe to the goal position (and possibly orientation) while avoiding contact by the concentric tube probe with one or more obstacles and for configuring the concentric tube probe as specified by the motion plan.

公开(公告)号：US11192945B2

公开(公告)日：2021-12-07

申请号：US14582631

申请日：2014-12-24

Applicant: Vanderbilt University ,  Vanderbilt University

Inventor： James R. Edwards ,  Gregory R. Mundy

IPC: A61K39/395 ,  C07K16/22 ,  A61P19/08 ,  A61P19/10 ,  C07K16/24 ,  A61K39/00

Abstract: The invention regards the modulation of TGF-β activity by administering to a subject an antibody that binds to TGF-β, thereby increasing bone growth, bone formation, bone mass and bone strength. The antibody acts to increase osteoblast number and function while at the same time decreasing osteoclast number and function. Such drugs are useful in the treatment of diseases or disorders such as osteoporosis, Paget's disease, metastatic bone cancer, myeloma bone disease, bone fractures, etc.

公开(公告)号：US20250041854A1

公开(公告)日：2025-02-06

申请号：US18918488

申请日：2024-10-17

Applicant: VANDERBILT UNIVERSITY

Inventor： Ronald S. Reiserer ,  John P. Wikswo

IPC: B01L3/00 ,  F04B43/06 ,  F04B43/14 ,  F16K99/00

Abstract: A fluidic system includes a systemic circulation and mixing reservoir, at least one flow bus, and at least one pump, fluidically coupled to one another, creating a fluidic network therewith; a delivering means fluidically coupled to the at least one pump; and a plurality of fluidic modules, each fluidic module having an input port fluidically coupled to the delivering means, and an output port fluidically coupled to one of the at least one flow bus. In operation, the at least one pump withdraws media from the systemic circulation and mixing reservoir and delivers the media to the delivering means that in turn delivers the media to the plurality of fluidic modules individually, and then the effluent of the plurality of fluidic modules is delivered to the systemic circulation and mixing reservoir through said one of the at least one flow bus.

公开(公告)号：US20250026752A1

公开(公告)日：2025-01-23

申请号：US18700130

申请日：2022-10-14

Applicant: Vanderbilt University

Inventor： Craig W. Lindsley ,  P. Jeffrey Conn ,  Darren W. Engers ,  Julie L. Engers ,  Madeline F. Long ,  Logan A. Baker ,  Rory A. Capstick ,  Charlotte Park ,  Andrew S. Felts ,  Kayla J. Temple ,  Aaron M. Bender

IPC: C07D471/04 ,  A61K31/517 ,  A61K31/519 ,  A61K31/5377 ,  A61K31/538 ,  A61K31/5383 ,  C07D519/00

Abstract: Disclosed herein are analogs of 4-(7,8-dihydro-1,6-naphthyridin-6(5H)-yl)quinazoline and 4-(7,8-dihydro-1,6-naphthyridin-6(5H)-yl)pyrido[2,3-d]pyrimidine, which may be useful as positive allosteric modulators of the muscarinic acetylcholine receptor M4 (mAChR M4). Also disclosed herein are methods of making the compounds, pharmaceutical compositions comprising the compounds, and methods of treating neurological and psychiatric disorders associated with muscarinic acetylcholine receptor dysfunction using the compounds and compositions.

公开(公告)号：US20250024832A1

公开(公告)日：2025-01-23

申请号：US18684418

申请日：2022-08-19

Applicant: VANDERBILT UNIVERSITY

Inventor： Wei K. Wu ,  Matthew Bacchetta ,  Sophoclis Alexopoulos ,  John W. Stokes ,  Rei Ukita ,  Yatrik J. Patel

IPC: A01N1/02

Abstract: A system for maintaining immune separation between an extracorporeal organ and a bioreactor includes an organ chamber holding an extracorporeal organ and a cross-circulation circuit connecting the extracorporeal organ with the bioreactor. The cross-circulation circuit can direct the flow of perfusate therebetween. The bioreactor may include an allogeneic or xenogeneic host organism. for example a swine host. The cross-circulation circuit comprises at least one semipermeable membrane configured to establish an immunologic barrier to maintain separation between the immune responses of the bioreactor and the extracorporeal organ and to maintain physiologic stability of the bioreactor and the extracorporeal organ. The immune-reduced cross-circulation circuit may improve extracorporeal organ viability for research and transplant purposes.

公开(公告)号：US20250006342A1

公开(公告)日：2025-01-02

申请号：US18698611

申请日：2022-10-04

Applicant: VANDERBILT UNIVERSITY ,  INNERWORLD, INC.

Inventor： Noah ROBINSON ,  Callum GOLDS ,  Tanner NETTERVILLE

IPC: G16H20/70 ,  G06F3/01 ,  G06T13/40 ,  G10L15/26 ,  G16H10/20 ,  G16H40/67 ,  G16H50/20

Abstract: Systems and methods are provided for providing mental health intervention using a virtual environment. A spoken communication from a first user is conveyed to a second user in a virtual environment. Data about the first user is collected as the first user interacts with the second user. The collected data includes tone information from the spoken communication. A clinical parameter representing a mental state of the first user is determined from the collected data at a machine learning model. A prompt is provided to the second user, representing one of a suggested phrase, a suggested sentence, and a suggested topic of conversation, according to the determined clinical parameter.

公开(公告)号：US20250002507A1

公开(公告)日：2025-01-02

申请号：US18700101

申请日：2022-10-14

Applicant: Vanderbilt University

Inventor： Craig W. Lindsley ,  P. Jeffrey Conn ,  Darren W. Engers ,  Alison R. Gregro ,  Katrina A. Bollinger ,  Charlotte Park ,  Kayla J. Temple ,  Logan A. Baker ,  Madeline F. Long ,  Anna E. Ringuette ,  Julie L. Engers

IPC: C07D519/00 ,  A61K31/5025

Abstract: The present invention relates to 6-([1,2,4]triazolo[4,3-b]pyridazin-6-yl)-7,8-dihydro-5H-1,6-naphthyridine derivatives, 6-(imidazo[1,2-b]pyridazin-6-yl)-7,8-dihydro-5H-1,6-naphthyridine derivatives or 6-(imidazo[1,5-b]pyridazin-6-yl)-7,8-dihydro-5H-1,6-naphthyridine derivatives of formula (I) The present compounds are positive allosteric modulators of the muscarinic acetylcholine receptor M4 (mAChR M4) for use in treating neurological and psychiatric disorders associated with muscarinic acetylcholine receptor dysfunction. An exemplary compound is e.g. compound 1 Data on the activity of exemplary compounds in an mAChR M4 cell-based assay is provided. wherein: Z1 is CR1; Z2 is CR2; Z3 is CR3; Z4 is N; R1 is hydrogen, C1-4alkyl, or OC1-4alkyl; R2 is G2, R, C1-6alkyl, halogen, C1-6haloalkyl, —ORb, -L-ORb, -L-R, -L-G2, -L(OH)-G2, or hydrogen; R3 is hydrogen; 1
6-(7,8-dimethyl- [1,2,4]triazolo[4,3- b]pyridazin-6-yl)- 7,8-dihydro- 5H-1,6-naphthyridine

公开(公告)号：US12168129B2

公开(公告)日：2024-12-17

申请号：US18391840

申请日：2023-12-21

Applicant: VANDERBILT UNIVERSITY

Inventor： Jack H. Noble ,  Robert F. Labadie ,  Benoit M. Dawant

IPC: A61N1/36 ,  A61B5/055 ,  A61B5/107 ,  A61B34/10 ,  A61N1/05 ,  G06T7/12 ,  G06T7/181 ,  G06T11/00 ,  A61B6/03

Abstract: A patient-customized electrode array (EA) includes a plurality of electrodes, {Ei}, assembled in a pre-curved form, wherein the curvature of the EA at the i-th electrode Ei is characterized with a curvature that matches the curvature of the i-th point Pi of a structure curve in the cochlea of a patient where the i-th electrode Ei is to be placed, wherein i=1, 2, 3, . . . N, N is an integer greater than zero.

公开(公告)号：US20240409938A1

公开(公告)日：2024-12-12

申请号：US18737720

申请日：2024-06-07

Applicant: Vanderbilt University

Inventor： Craig L. Duvall ,  Ethan S. Lippmann ,  Alexander G. Sorets

IPC: C12N15/113 ,  A61K47/10 ,  A61K47/20 ,  A61K47/26 ,  A61K47/42 ,  A61K47/54

Abstract: Disclosed herein are methods of treating central nervous system diseases, such as Alzheimer's disease and Huntington's disease, using lipophilic siRNA conjugates that can bind to albumin. The disclosed methods can advantageously provide widespread, long-term gene silencing in the central nervous system. An example method includes administering to a subject an effective amount of a conjugate, optionally in combination with a pharmaceutically acceptable excipient, wherein the conjugate includes a siRNA capable of inhibiting expression of a protein associated with the central nervous system disease; a lipophilic ligand capable of binding albumin; and a linker attaching the siRNA to the lipophilic ligand, the linker including a branching molecule attached to the siRNA, and a hydrophilic spacer attaching the branching molecule to the lipophilic ligand.

公开(公告)号：US20240390486A1

公开(公告)日：2024-11-28

申请号：US18695945

申请日：2022-10-06

Applicant: Vanderbilt University

Inventor： Benjamin W. Spiller ,  Scott A. Smith

IPC: A61K39/35 ,  A61P37/08 ,  G01N33/68

Abstract: Disclosed herein is a composition comprising a mutant peanut (Arachis hypogaea) Ara h 6 polypeptide, a mutant Ara h 2 polypeptide, or a combination thereof in a pharmaceutically acceptable carrier, wherein the mutant Ara h 6 polypeptide and/or mutant Ara h 2 polypeptide has a reduced IgE response in a subject with a peanut allergy compared to wildtype Ara h 6 or Ara h 2 polypeptide. Also disclosed is a method for desensitizing or tolerizing a subject with a peanut allergy, comprising administering to the subject the mutant peanut Ara h 6 and/or Ara h 2 polypeptides disclosed herein. Also disclosed is a method for monitoring progress for the disclosed therapeutic methods.